Sentences with word «axicabtagene»
The FDA has approved the CAR T - cell therapy axicabtagene ciloleucel (Yescarta) for the treatment of large B - cell lymphomas in adults who have failed or relapsed after two or more prior treatments.
cancernetwork.com
Kite Pharma today reported positive 6 - month data from its pivotal ZUMA - 1 trial for its lead chimeric antigen receptor (CAR) T - cell candidate axicabtagene ciloleucel (formerly KTE - C19) in patients with chemorefractory aggressive B - cell non-Hodgkin lymphoma (NHL).
City of Hope will be the one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. Food and Drug Administration (FDA) announced today is the first approved CAR T therapy for adult patients who have not responded to or who have relapsed after at least two other kinds of treatment.
Other CAR T - cell therapies approved in 2017 include tisagenlecleucel for the treatment of children and young adults up to 25 years of age with relapsed or refractory B - cell precursor acute lymphoblastic leukemia and axicabtagene ciloleucil (aci - cel; Yescarta) for adults with relapsed or refractory DLBCL.
As of October 2017, adult patients with several forms of non-Hodgkin lymphoma can be treated with a CAR T cell immunotherapy known as axicabtagene ciloleucel (Yescarta ™).
Dr. Locke participated in the clinical trials that led to US Food and Drug Administration approval of a novel chimeric antigen receptor (CAR) T - cell therapy called axicabtagene ciloleucel.
Cancer Network: Can you tell us what CAR T - cell therapy is in general and then describe axicabtagene ciloleucel specifically?
In October, the FDA approved a second CAR - T therapy, axicabtagene ciloleucel (developed by Kite Pharma and dubbed Yescarta), for patients with relapsed or refractory non-Hodgkin lymphoma.
The FDA granted approval to Yescarta ™ (axicabtagene ciloleucel, Kite / Gilead) for the treatment of adult patients with several types of non-Hogdkin large B cell lymphoma that is refractory or has relapsed after at least two previous systemic treatments.